SOURCE: Amarillo Biosciences, Inc.

July 07, 2006 10:54 ET

Amarillo Biosciences Submits Investigational New Drug Application to Test Oral Interferon in Idiopathic Pulmonary Fibrosis

Company to Fund Chicken Influenza Study; Retains RiverStone Wealth Management

AMARILLO, TX -- (MARKET WIRE) -- July 7, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it submitted an Investigational New Drug (IND) Application to the FDA to begin a study of orally delivered interferon alpha in 60 patients with idiopathic pulmonary fibrosis (IPF). These IPF patients will be enrolled from approximately six clinical sites in the US. The patients will be given interferon or placebo for four weeks to assess the effect of treatment on chronic cough. Approximately 85%-90% of IPF patients complain of a bothersome persistent cough that negatively impacts their quality of life. This trial is a follow-up to a positive pilot study conducted by investigators at the Texas Tech University Health Sciences Center, in which 5 of 6 IPF patients given orally administered IFN-alpha reported a significant reduction in chronic cough with corresponding improvement in their quality of life.

Separately, the Company announced that it is funding an influenza chicken study with Benchmark BioLabs of Lincoln, Nebraska (www.benchmarkbiolabs.com). The new study will determine the effectiveness of oral interferon alpha against influenza in chickens. It has already been published that, in chickens, orally administered interferon is safe and effective against two fatal viral infections of poultry, i.e., Newcastle disease and infectious bronchitis disease. "It makes sense to put interferon in the water of birds with influenza to reduce the amount of influenza virus excretion and thereby reduce the threat of infection to human personnel responsible for killing and disposing of infected birds. This study will supplement data generated in 4 studies in mice that have been completed in recent months, all of which support the conclusion that oral interferon provides significant prophylactic and therapeutic benefit to animals exposed to a lethal strain of influenza," said Joseph Cummins, CEO of ABI.

The Company has retained RiverStone Wealth Management LLC of Austin, Texas to assist it in completing a private placement of the Company's common stock.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 14% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

Contact Information

  • Contacts:
    Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276
    e-mail: Email Contact

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301
    e-mail: Email Contact